Drug intelligence / Profile preview

LPT-99

Development stage: Unknown
Lead developer: Spiral Therapeutics
Modality: Small Molecules
Administration: Intratympanic

Overview

LPT-99 is a small molecule drug that acts as an inhibitor of apoptotic protease-activating factor 1 (APAF1). It was initially developed by Loop Therapeutics and is being further developed by Spiral Therapeutics for the prevention and treatment of hearing loss, particularly to protect against cisplatin-induced ototoxicity. Preclinical studies have shown that LPT-99 can reduce apoptosis in cochlear cells exposed to cisplatin, thereby preserving auditory function. The drug has demonstrated dose-dependent protective effects on auditory function in animal models and improved cell survival in vitro. Its mechanism involves inhibition of APAF1, which plays a key role in the intrinsic pathway of apoptosis[1][3][4][5].

Other names: LPT 99LPT99LPT-99

Targets

APAF1 (Apoptotic protease-activating factor 1)

Beyond the preview

Go deeper on LPT-99.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-99.

Explore the full profile